Canaccord Genuity published a Flash Report on Pandora Media Inc. (NYSE:P) on March 3rd, after the company reported strong listener numbers for March. Pandora took a hit after their last earnings report in early February.Pandora Media Inc. (NYSE:P) shares after opening at $32.61 moved to $33.70 on last trade day and at the end of the day closed at $29.85. Company price to sales ratio in past twelve months was calculated as 10.02 and price to cash ratio as 13.16. Pandora Media Inc. (NYSE:P) showed a positive weekly performance of 0.20%.
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of CytRx Corp. (NASDAQ:CYTR). CytRx is a California-based biopharmaceutical company specializing in oncology. CytRx Corporation (NASDAQ:CYTR) shares advanced 3.67% in last trading session and ended the day on $3.95. CYTR return on equity ratio is recorded as -287.90% and its return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR) yearly performance is 50.19%.
FireEye Inc. (NASDAQ:FEYE), the leader in stopping advanced cyber-attacks, on 1 April announced it has been awarded a 5-Star rating in the CRN 2014 Partner Program Guide. FireEye Inc. (NASDAQ:FEYE) shares moved down -10.78% in last trading session and was closed at $54.86, while trading in range of $54.65 – $62.00. FireEye Inc. (NASDAQ:FEYE) year to date (YTD) performance is 25.80%.
CELLDEX THERAPEUTICS, Inc. (NASDAQ:CLDX) announced yesterday that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate (ADC) CDX-014 will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1 (T cell immunoglobulin and mucin domain), which is upregulated in several cancers, including renal and ovarian carcinomas. Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is -11.93%. On last trading day company shares ended up $16.39. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -35.01%. Analysts mean target price for the company is $36.33.